S*BIO Commences Phase 1 of Clinical Trial
- Posted on 04 December 2008
Singapore-based company S*BIO has initiated phase 1 of the clinical trial for SB1518, a potent and orally-active Janus kinase 2 (JAK2) inhibitor.
This is being carried out in medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF).
The trial is designed to evaluate the safety and tolerability of the inhibitor in patients with CIMF and is expected to enroll up to 50 patients.
Phase 1 will assess the safety profile and evaluate the pharmacokinetic and pharmacodynamic activities of SB1518. Phase 2 will assess clinical benefits and continue to evaluate the safety profile of the inhibitor.
